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ARTICLE
RUNX1/RUNX1T1 mediates alternative splicing
and reorganises the transcriptional landscape
in leukemia
Vasily V. Grinev 1✉, Farnaz Barneh2, Ilya M. Ilyushonak1, Sirintra Nakjang3, Job Smink2, Anita van Oort2,
Richard Clough 3, Michael Seyani3, Hesta McNeill3, Mojgan Reza3, Natalia Martinez-Soria3, Salam A. Assi4,
Tatsiana V. Ramanouskaya1, Constanze Bonifer 4 & Olaf Heidenreich 2,3,5✉
The fusion oncogene RUNX1/RUNX1T1 encodes an aberrant transcription factor, which plays a
key role in the initiation and maintenance of acute myeloid leukemia. Here we show that the
RUNX1/RUNX1T1 oncogene is a regulator of alternative RNA splicing in leukemic cells. The
comprehensive analysis of RUNX1/RUNX1T1-associated splicing events identifies two princi-
pal mechanisms that underlie the differential production of RNA isoforms: (i) RUNX1/
RUNX1T1-mediated regulation of alternative transcription start site selection, and (ii) direct or
indirect control of the expression of genes encoding splicing factors. The first mechanism
leads to the expression of RNA isoforms with alternative structure of the 5’-UTR regions. The
second mechanism generates alternative transcripts with new junctions between internal
cassettes and constitutive exons. We also show that RUNX1/RUNX1T1-mediated differential
splicing affects several functional groups of genes and produces proteins with unique con-
served domain structures. In summary, this study reveals alternative splicing as an important
component of transcriptome re-organization in leukemia by an aberrant transcriptional
regulator.
https://doi.org/10.1038/s41467-020-20848-z OPEN
1 Department of Genetics, Faculty of Biology, Belarusian State University, 220030 Minsk, Republic of Belarus. 2 Princess Maxima Center for Pediatric
Oncology, 3584 CS Utrecht, The Netherlands. 3Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle
University, Newcastle upon Tyne NE1 7RU, UK. 4 Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of
Birmingham, Birmingham B15 2TT, UK. 5 Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
✉email: grinev_vv@bsu.by; o.t.heidenreich@prinsesmaximacentrum.nl









A lternative splicing increases the transcriptomic and pro-teomic complexity by generating distinct RNA isoformswith different roles and functions from a single gene1.
When dysregulated, alternative splicing can contribute to
tumorigenesis2,3. Dysregulation can take place on the level of
alternative promoter choice leading the transcripts with altered
5’-termini, choice of alternative polyadenylation, and within
transcript bodies by changes in splice site selection affecting exon
composition or intron retention. Mis-splicing of genes has been
found in multiple malignancies including carcinomas, neuro-
blastoma, chronic lymphoid leukemia and acute myeloid leuke-
mia (AML)4. Mutations in spliceosome factor genes such as
SF3B1, SRSF2, or U2AF are frequently found in myelodysplastic
syndrome and are currently intensively examined for their ther-
apeutic relevance5–7.
Alternative splicing is also regulated by epigenetic marks8,9.
Histone modifications and DNA methylation can affect exon
usage by controlling the elongation speed of RNA polymerase II
(RNA pol II) and, consequently, the choice of splice sites.
Furthermore, they may affect the recruitment of splicing factors
to chromatin through adapters such as CHD1. Moreover,
chromatin modifications have been found to regulate the
activity of alternative or cryptic transcriptional start sites (TSSs)
in the genome10. Indeed, deregulation of alternative promoter
usage has been recently identified as a common phenomenon in
cancer11. However, underlying genetic reasons for alternative
promoter choice are largely unknown.
The fusion oncogene RUNX1/RUNX1T1 is expressed as a
result of the chromosomal translocation t(8;21), which involves
the RUNX1 gene on chromosome 21 and the RUNX1T1 gene
on chromosome 812. When expressed in haematopoietic cells,
the fusion protein occupies more than 4000 genomic sites and
forms transcription regulatory complexes by recruiting co-
factors13–18. These complexes trigger a local remodeling of
chromatin of a wide range of genes and thereby affect their
expression13,19,20. In turn, the change of target gene expression
leads to a block of cell differentiation, enhancement of self-
renewal, modulation of the apoptosis and, eventually, to
malignant transformation of t(8;21)-positive cells15,21–23.
However, despite increasing knowledge of the molecular
function of RUNX1/RUNX1T1, its impact on the leukemic
transcriptome is still only incompletely understood. More
generally, a potential role of leukemic fusion genes encoding
epigenetic modulators such as RUNX1/RUNX1T1 has not yet
been established for the regulation of alternative splicing.
To address this question, we performed perturbation
experiments in t(8;21)-positive AML cells and examined the
impact of RUNX1/RUNX1T1 knockdown on the gene expres-
sion and RNA splicing at a global level. Our results demon-
strate that RUNX1/RUNX1T1 downregulation affects splicing
of both direct target genes and in an indirect fashion.
Mechanistically, changes in the production of RNA isoforms
are implemented via (i) direct control of alternative tran-
scription start site selection in target genes, and (ii) by direct or
indirect control of the expression of the genes encoding spli-
cing factors. Our modeling and experimental results indicate
that oncoprotein-mediated differential splicing affects con-
served domain structures in proteins, ultimately modulating
leukemia-relevant processes such as nucleotide metabolism,
cell adhesion and cell differentiation.
In conclusion, our results show that the fusion
oncogene RUNX1/RUNX1T1 controls alternative splicing in
AML. These findings add to the complexity in the organization
of leukemia-driving transcriptomes and set a paradigm for the
role of fusion gene-encoded transcription factors in RNA
processing.
Results
Change in the expression of the fusion oncogene RUNX1/
RUNX1T1 leads to differential splicing in the leukemic tran-
scriptome. To detect a potential association between RUNX1/
RUNX1T1 and RNA splicing, we initially analyzed published
RNA-seq, ChIP-seq and DNase-hypersensitive-site-seq (DHS-
seq) data sets for links between RUNX1/RUNX1T1 and RNA
processing (Supplementary Data 1). Functional annotation by
DAVID uncovered a highly significant enrichment of RUNX1/
RUNX1T1 binding at gene loci that are subject to alternative
splicing and splice variants (false discovery rate adjusted p-value
or q-value, 4.0 × 10−23 and 1.5 × 10−12, respectively; Supple-
mentary Fig. 1a, Supplementary Data 2)24. These findings are in
line with the observation that RUNX1/RUNX1T1 may interact
with several splicing factors implying a direct link between
RUNX1/RUNX1T1-regulated transcription and RNA proces-
sing15. Furthermore, we observed that RUNX1/RUNX1T1 bind-
ing sites are often present within genes encoding splicing-
associated factors or in their immediate vicinity (Supplementary
Data 3, 4). The list of such genes includes both classical splicing
regulatory genes such as HNRNPM, RBFOX2, SF3A3, SRSF5, and
genes encoding the components of nuclear speckles including
RBM6, SNRPD3, SNU13, which are considered the area of
intensive splicing25,26. Moreover, gene set enrichment analysis
(GSEA) suggests that knockdown of RUNX1/RUNX1T1 affects
RNA binding proteins and snRNP assembly, and is associated
with impaired mRNA processing and, in particular, splicing
pathways (Fig. 1a; Supplementary Fig. 1b)27. These findings
strongly suggest a regulatory role of this leukemic fusion protein
in mRNA splicing and predict changes in splicing pattern in
response to perturbing RUNX1/RUNX1T1 activity.
To identify differential splicing events regulated by RUNX1/
RUNX1T1, we analyzed RNA-Seq data of the t(8;21)-positive
AML cell line Kasumi-1 following RUNX1/RUNX1T1 knockdown
(Supplementary Data 1, GSE54478). Knockdown was achieved by
electroporation with the short interfering RNA (siRNA) siRR
targeting the fusion site of the RUNX1/RUNX1T1 mRNA, while a
mismatch siRNA, siMM, served as a control28 (Fig. 1b).
The differential splicing events were detected at the level of
both exons and exon-exon junctions (EEJs). Differentially used
exons (diffUEs) were identified by use of DEXSeq, limma/
diffSplice and JunctionSeq, while differentially used exon-exon
junctions (diffEEJs) were identified using limma/diffSplice and
JunctionSeq functionality29–31. This combined approach detected
a comprehensive set of differential splicing events in dependence
on the RUNX1/RUNX1T1 status.
Using our pipeline, we developed a list of non-overlapping
genomic fragments by analyzing 511,363 non-overlapping bins of
human canonical exons annotated in Ensembl32. This exonic list
was extended by 3540 non-overlapping bins of retained introns
detected in 2401 genes of the Kasumi-1 cells, of which 25% were
differentially retained between RUNX1/RUNX1T1 knockdown
and control cells (Supplementary Data 5). Of note, knockdown
affected intron retention in both ways: 419 introns were
exclusively detected in RUNX1/RUNX1T1-depleted cells, while
469 introns were only retained in control cells (Fig. 1c, d;
Supplementary Fig. 1c, d). These condition-specific retained
introns show a small but noticeable difference in expression
(Supplementary Fig. 1e–i).
In addition to differentially retained introns, we identified 395
differentially used exons (diffUEs) in the Kasumi-1 transcriptome
following RUNX1/RUNX1T1 knockdown (Fig. 1e, f; Supplemen-
tary Fig. 1j; Supplementary Data 6). The list of the identified
diffUEs included 387 canonical exons and 8 retained introns
affecting 275 genes (Fig. 1g, h). Interestingly, while these diffUEs
were uniformly distributed across non-coding RNAs, in protein-
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coding transcripts they were significantly enriched for 5’-UTR
exons and depleted for CDS, 3’-UTR and multi-type exons
(Fig. 1i).
At the level of EEJs, we detected 177 differentially used EEJs
(diffEEJs) upon RUNX1/RUNX1T1 knockdown that were dis-
tributed over 150 genes (Fig. 2a–c; Supplementary Fig. 2a;
Supplementary Data 7). These diffEEJs belonged to the main
modes of alternative splicing (Fig. 2d) and associated with all
functional types of exons (Fig. 2e). In contrast to genes with
condition-specific retained introns, only 55 of 378 genes with
diffUEs or diffEEJs showed changes in total transcript levels upon
RUNX1/RUNX1T1 knockdown (Supplementary Fig. 2b, c).
Notably, use of two different algorithms limma/diffSplice and
JunctionSeq for the analysis of diffEEJs produced only minimally
overlapping results (Fig. 2b, c). This is due to the differences in
the pre-processing, filtering, normalization and transformation of
the data, as well as in the use of different statistical models at the
step of identification of diffEEJs by the algorithms. However,
diffEEJs identified by both limma/diffSplice and JunctionSeq
could be confirmed using qRT-PCR (Supplementary Data 8).
RUNX1/RUNX1T-associated alternatively spliced variants are
distinctive features in primary leukemia samples. To examine
whether diffEEJs detected in Kasumi-1 cells are also present in
Fig. 1 Knockdown of RUNX1/RUNX1T1 affects exon usage in Kasumi-1 cells. a Gene set enrichment analysis plots for RNA binding proteins55 and the
Reactome snRNP assembly pathway. NES, normalized enrichment score; q, false discovery rate. b Western blot of RUNX1 and RUNX1/RUNX1T1 protein
levels in Kasumi-1 cells following RUNX1/RUNX1T1 knockdown. A representative result from one of the three experiments is shown. siMM, mismatch
siRNA; siRR, RUNX1/RUNX1T1 siRNA. c Distribution of retained introns (RIs) between the transcriptomes of the siRR-treated and siMM-treated Kasumi-
1 cells. The RIs were detected using the DESeq2 and edgeR/limma algorithms. d Scatter plot showing the distribution of siRR-specific and siMM-specific
RIs after multidimensional reduction of RIs expression data using t-distributed stochastic neighbor embedding. The RIs were detected using the edgeR/
limma algorithm, and very similar results were observed with DESeq2. e, f Vulcano plots showing differential usage of exons identified by DEXSeq e or
limma/diffSplice f algorithms. Orange and yellow rhombi indicated differentially used canonical exons or RIs, respectively, with more than 2-fold change
and q < 0.1. g Venn diagram showing overlap between differentially used exons (diffUEs) identified by DEXSeq, limma/diffSplice and JunctionSeq
algorithms. h Venn diagram showing overlap of genes with diffUEs identified by the DEXSeq, limma/diffSplice and JunctionSeq algorithms. i Classification
of diffUEs according to the functional type of exons. Genomic coordinates of the reference exons were extracted from Ensembl models of the human genes.
diffUEs were intersected with reference exons and the overlaps counted. Fisher’s two-sided exact test was performed to detect over-represented or under-
represented exon types among the diffUEs against non-differential exons (non-diffUEs).
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primary leukemia blasts, we selected publicly available RNA-Seq
samples from 20 patients with t(8;21)-positive AML (Supplemen-
tary Data 1, GSE62190 and GSE67040). With this dataset we
detected about 80% of Kasumi-1-associated diffEEJs that are
abundant in the transcriptome of primary t(8;21)-positive leukemia
blasts (Fig. 3a). This extensive overlap is in line with the previously
observed high correlation between t(8;21)-positive cell lines and
patient material regarding gene expression and chromatin accessi-
bility, and proves Kasumi-1 as a relevant model system for RUNX1/
RUNX1T1-regulated gene expression19,21,23,33.
Next, we tested if these splicing events were specific features of
t(8;21)-positive AML by comparing splicing events found in
t(8;21) AML cells with those in normal cells or cells from other
AML subtypes (Supplementary Data 1). To that end we analyzed
RNA-Seq data from normal CD34-positive cells obtained from
human bone marrow (GSE102881, GSE111085, GSE63569, and
GSE69239), umbilical cord blood (GSE48846, GSE69905, and
GSE71689) and peripheral blood (GSE102881, GSE107218,
GSE68925, GSE87285, GSE90552 and GSE92274) in addition to
AML cells with normal karyotype (GSE49642 and GSE52656),
inv(16) (GSE108266, GSE62190, and GSE67039) or a rearranged
MLL locus (GSE52656, GSE62190, and GSE67039). With this
comprehensive dataset, independent component analysis revealed
three independent subsets of EEJs that clearly separate t(8;21)-
positive AML cells from normal CD34-positive cells (Fig. 3b;
Supplementary Data 9). We found that 53% of diffEEJs identified
in Kasumi-1 were present in these independent components with
high statistical significance (odds ratio 5.42, p < 2.2 × 10−16). A
similar result was obtained when comparing t(8;21)-positive cells
with other types of leukemia (Fig. 3c; Supplementary Data 10)
with 48% of those diffEEJs identified in Kasumi-1 contributing to
the discrimination of t(8;21)-positive AML from other AML
subtypes (odds ratio 2.67, p= 4.1 × 10−12).
Together, these results clearly indicate that RUNX1/
RUNX1T1-dependent splicing events are characterizing features
of the transcriptome of t(8;21)-positive AML cells. The
occurrence of these events in combination with selected
RUNX1/RUNX1T1-independent splicing events distinguishes
t(8;21)-positive from t(8;21)-negative AML cells and normal
haematopoietic stem and progenitor cells.
Fig. 2 Knockdown of RUNX1/RUNX1T1 causes changes in exon-exon linkages in leukemic cells. a Vulcano plot showing differential splicing of exons
identified by limma/diffSplice algorithm. Orange rhombi indicated differentially used exon-exon junctions (diffEEJs) with more than 2-fold change and q <
0.1. b Venn diagramme showing the overlap between diffEEJs identified by limma/diffSplice and JunctionSeq algorithms. c Venn diagramme showing
overlap of genes with diffUEs identified by limma/diffSplice and JunctionSeq algorithms. d Pie charts showing the classification of diffEEJs and non-
differential exon-exon junctions (non-diffEEJs) according to the modes of alternative splicing. Numbers indicate the percentage of splicing events assigned
to a particular mode of splicing. Complex splicing means several (two or more) alternative splicing events occurred simultaneously. e Distribution of the
splice sites with diffEEJs and non-diffEEJs among the various functional types of exons. P-values were calculated with χ2 test. Panels a to e are based on
data from Kasumi-1 cells.
Fig. 3 RUNX1/RUNX1T1-associated alternatively spliced variants are distinctive features in primary leukemia samples. a Violin plot showing the
enrichment level of Kasumi-1 exon-exon junctions in the transcriptome of primary t(8;21)-positive leukemia blasts from 20 patient samples. P-values were
calculated with two-sided Mann–Whitney U test. b, c Independent component analysis of t(8;21)-positive AML cells with normal CD34-positive cells b or
other AML subtypes c. This analysis included 20 samples of each cell type. For each sample, the expression of 84,743 exon-exon junctions was quantified.
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Modulation of local epigenetic marks by RUNX1/RUNX1T1
influences alternative splicing. Next, we determined the
mechanisms through which RUNX1/RUNX1T1 controls splicing
events in t(8;21)-driven leukemia. Binding of RUNX1/RUNX1T1
at specific genomic sites affects the local chromatin status,
including changes in histone modifications and chromatin
accessibility14,19,20 (Fig. 4a, H3K9Ac data). These epigenetic
changes were associated with the redistribution of RNA pol II
peaks indicating changes in transcription rates upon RUNX1/
RUNX1T1 knockdown (Fig. 4a, RNA pol II data).
Since transcription kinetics can affect alternative splicing34,35,
we examined the potential impact of RUNX1/RUNX1T1-
dependent chromatin organization and transcription upon
splicing events in more detail. Splice sites of diffEEJs were
significantly enriched in the regions of open chromatin (marked
by DNase I hypersensitivity sites and sites of H3K9Ac histone
modification) and decelerated RNA pol II elongation compared
to the splice sites of non-diffEEJs (Fig. 4b). Comparison of
canonical splice sites with diffEEJs demonstrated a closer
proximity of alternative 5’ splice sites (but not 3’ splice sites) to
open chromatin regions, and sites bound by H3K9Ac and RNA
pol II (Fig. 4c). Similarly, alternative 5’ splice sites showed also a
trend towards closer proximity to RUNX1/RUNX1T1 sites. These
data suggest that splice sites of diffEEJs, which are occupied by
H3K9Ac and RNA pol II, are controlled by RUNX1/RUNX1T1.
All of the above findings indicate a close association between
chromatin state and differential splicing following RUNX1/
RUNX1T1 knockdown. Since the epigenetic landscape affects
alternative splicing only in cooperation with sequence features of
pre-mRNA36, we integrated epigenetic data with multivariate
sequence data and calculated the partial dependence for each
epigenetic mark using a random forest approach (see Supple-
mentary Methods for further details). This analysis demonstrates
that differential splicing is promoted by proximity to RUNX1/
RUNX1T1, RNA pol II, and H3K9Ac sites, as well as DNase I
hypersensitivity sites (Fig. 4d) and highlights the influence of the
chromatin state on differential splicing following RUNX1/
RUNX1T1 knockdown.
Delayed splicing is sensitive to regulation by RUNX1/
RUNX1T1. The majority of splicing events are co-transcriptional.
However, in some cases of regulated alternative splicing, intron
removal can be delayed until the release of pre-mRNA from the
site of transcription37,38. With this in mind, we analyzed nascent
RNA in Kasumi-1 cells for EEJs that were shared between nascent
and total, i.e., mature RNA (Fig. 5a). These EEJs were grouped
into two classes. The first class (non-diffEEJs) included the nas-
cent EEJs which did not become differential EEJs at the level of
total RNA. In contrast, the second class (diffEEJs) collected events
that were identified as diffEEJs at the level of total RNA.
Interestingly, expression of diffEEJs (affected by RUNX1/
RUNX1T1 knockdown; Fig. 5b) showed a much stronger bimodal
distribution resulting in a lower median compared to non-
diffEEJs (Fig. 5c, Supplementary Table 1). For the nascent RNA,
the number of low abundant diffEEJs substantially exceeded
that of high abundant ones, while the opposite was true for total
RNA. In contrast, the distribution pattern of non-diffEEJs shifted
only slightly towards higher abundances. Importantly, neither
Fig. 4 RUNX1/RUNX1T1-dependent differential splicing events in Kasumi-1 cells are associated with open chromatin. a Column graph showing the
distribution of RUNX1/RUNX1T1, H3K9Ac and RNA pol II occupied sites with or without RUNX1/RUNX1T1 knockdown. The top panel shows the
distribution for all sites, the bottom panel only shows distribution of binding sites overlapping with the 5’ splice sites of diffEEJs. b Association of diffEEJs
splice sites with open chromatin. P-values were calculated with Fisher’s two-sided exact test. c Violin graph depicting the positional relationships between
canonical (c; n= 117) and alternative (a; n= 57) 5’ splice sites of diffEEJs and marks of open chromatin. P-values were calculated with two-sided
Mann–Whitney U test. Yellow horizontal thick lines represent the median of distances distribution, the black vertical rectangular boxes show the
interquartile range, and the black vertical lines are the 95% confidential interval. d Effect of the proximity to RUNX1/RUNX1T1 binding sites, RNA pol II
peaks, H3K9Ac histone modifications and DNase I hypersensitivity sites on the probability of the diffEEJs and non-diffEEJs in the transcriptome of
leukemia cells.
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expression levels of differentially spliced versus non-differentially
spliced genes nor the distribution of intron lengths differed
substantially between non-diffEEJs and diffEEJs and, thus, are not
the cause for the observed shifts (Fig. 5e, f). Therefore, these
findings suggest the presence of differential splicing events which
undergo delayed processing. Furthermore, they imply that
delayed splicing is more sensitive to genomic and transcriptomic
perturbations induced by the changes in the RUNX1/RUNX1T1
expression.
Differential splicing produces proteins with unique conserved
domain structures and affects multiple cellular processes. Next,
we assessed in silico the potential functional consequences of
RUNX1/RUNX1T1-associated differential splicing. Enrichment
analysis with Gene Ontology gene sets suggested that differential
splicing particularly affects genes controlling synthesis, transport,
targeting and localization of proteins, cell adhesion and granu-
locyte activation (Fig. 6a).
To further detail above functional findings, we used RNA-
Seq data (Supplementary Data 1, GSE54478) and Cufflinks/
Cuffdiff algorithm to assemble of full-length RNA molecules, as
well as to quantify their expression in Kasumi-1 cells. We found
that genes affected by RUNX1/RUNX1T1-dependent differential
splicing encode 752 transcripts, of which 214 isoforms were
differentially spliced. Here and below, the term “differentially
spliced isoform” indicates a molecule of RNA with at least one
differential exon-exon junction (upegulated or downregulated),
while a non-differential isoform is a transcript lacking any
diffEEJs.
Of all above transcripts, 75% were potentially protein coding,
while the rest were non-coding RNAs (Fig. 6b, c, upper panel).
We aligned in silico translated proteins against the human NCBI
RefSeq proteins (release 92, last modified on 18 March 2019) and
the newest non redundant releases of GenBank CDS translations,
UniProtKB/SwissProt, Protein Data Bank, Protein Information
Resource and Peptide/Protein Sequence Database proteins
(updated on 11 April 2019) using NCBI blastp39. Out of 1055
in silico translated proteins, 722 proteins were 90% or more
identical to the proteins annotated in the public databases
(Fig. 6c, bottom panel). Such proteins form a clear peak on the
Fig. 5 Formation of diffEEJs in Kasumi-1 cells is delayed compared to non-diffEEJs. a The basic alignment statistics for the nascent RNA and total RNA
datasets obtained from the siMM-treated leukemia cells. Bars represent mean ± SD of three independent experiments. Very similar results were observed
with siRR-treated cells. b siRNA-mediated knockdown of RUNX1/RUNX1T1 as measured by nascent RNA expression. Bars represent mean ± SD of three
independent experiments. c Multidensity plots of the abundance of EEJs identified in the nascent RNA (left panel) or total RNA (right panel). These plots
are based on the RNA-Seq data obtained from the siMM-treated or siRR-treated leukemia cells. All EEJs identified at the level of nascent RNA and total
RNA were grouped (see main text for further explanation of classification procedure) into non-diffEEJs or diffEEJs, and the abundance of these events was
plotted. Each line represents the data averaged over the three independent biological replicas. d Expression of genes without (non-diffEEJs genes, n=
10851) or with differential splicing (upregulated or downregulated diffEEJs genes, n= 85) at nascent RNA level. e Expression of genes without (non-diffEEJs
genes, n= 9836) or with differential splicing (upregulated or downregulated diffEEJs genes, n= 150) at total RNA level. f Comparison of intron lengths
between non-diffEEJs (n= 104925) and diffEEJs (n= 177). In d, e, and f, boxplots summarize the expression data averaged over the three independent
biological replicas. In each boxplot, horizontal line represents the median of expression distribution, box shows the interquartile range, and whiskers are the
minimum and maximum. P-values were calculated with two-sided Mann–Whitney U test.
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curve of identity distribution and, to reduce noise, only these
proteins were selected for downstream analysis.
A substantial fraction of in silico translated proteins was
similar to native human proteins (Fig. 6d). At the same time,
there were also different extended and truncated isoforms of
proteins. Such isoforms can potentially include new domains or
may lack domains important for proper protein binding,
localization and function, with other functional regions remain-
ing unaffected.
To further structural detail, we assigned SCOP domains for
highly identical in silico translated proteins using the SUPER-
FAMILY hidden Markov models, and we identified 225
conserved domains within these proteins (Structural Classifica-
tion of Proteins database, release 1.75, June 2009)40,41. Identified
domains belong to 146 domain families. About 45% of these
domain families are common for proteins translated from
differentially (upregulated or downregulated) and non-
differentially (no change) spliced RNA isoforms. However, 16%
of domain families are associated with differentially spliced RNA
isoforms. This uniqueness of differential proteins is robust and is
retained even when domains are combined into domain super-
families (Fig. 6e).
Finally, we used a domain-centric Gene Ontology method for
functional annotation of the domain architectures of in silico
predicted proteins42. We applied the enrichment test separately
for proteins translated from differentially spliced (upregulated or
downregulated) or non-differentially spliced RNA isoforms, and
we integrated the results using EnrichmentMap43. This in silico
approach showed that the domains encoded by differential RNA
isoforms are mainly involved in the global regulation of cellular
processes, molecular binding (including protein binding), trans-
port and localization of molecular substances, and cell commu-
nications (Fig. 6f).
RUNX1/RUNX1T1 affects differential splicing by controlling
alternative promoter usage. RUNX1/RUNX1T1 binding sites are
enriched in promoter and intronic regions indicating that the
fusion protein directly affects transcription of multiple
genes14,19,21. Consistently, in our dataset of diffUEs and diffEEJs,
we found that 38% of genes with differential splicing were also
enriched for fusion protein binding sites (Supplementary Data 6,
7). This enrichment was significantly higher than that for non-
differentially spliced genes (odds ratio 2.47 and p= 2.5 × 10−15
according to two-sided Fisher’s exact test). Based on these data,
Fig. 6 Fusion protein-controlled differential splicing expands the protein space. a Enrichment map of the Gene Ontology-enriched gene sets across all
the genes with differential expression and/or differential splicing. Nodes represent significantly enriched gene sets and node size is proportional to the
number of members in a gene set. Edges indicate the gene overlap between the nodes, and the thickness of the edges is equivalent to the degree of the
gene overlap between the nodes. Functionally related gene sets are clustered and named. b Box plot depicting the coding potential of 500 randomly
selected transcripts each from housekeeping genes and lincRNA genes, and all 752 transcripts of genes affected by differential splicing in Kasumi-1 cells. In
each boxplot, horizontal line represents the median of probability distribution, box shows the interquartile range, and whiskers are the minimum and
maximum. c Column graphs depicting the classification of coding sequences in transcripts (upper panel) and of in silico translated proteins (lower panel)
affected by differential splicing. In the upper panel, all transcripts were classified on non-coding (no significant open reading frames were found), protein-
coding with premature termination codons and protein-coding with mature termination codons. In the bottom panel, all protein-coding transcripts were in
silico translated and predicted proteins were blastp aligned against non-redundant set of human proteins. Protein identities are indicated at the bottom.
d Column graphs showing the impact of RUNX1/RUNX1T1 on the frequency of protein variants. e Venn diagramme visualizing the distribution of the 118
domain superfamilies among the in silico predicted proteins. f Enrichment map of the domain-centered Gene Ontology-enriched superfamily sets across all
the genes with differential splicing. Nodes represent significantly enriched superfamily sets and node size is proportional to the number of members in a
superfamily set. Edges indicate the superfamily overlap between the nodes, and the thickness of the edges is equivalent to the degree of the superfamily
overlap between the nodes. Functionally related superfamily sets are clustered and named. Pie chart coloring: (a) upregulated, (b) downregulated, and (c)
no change.
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we hypothesized that differential splicing events can arise from
the selection of alternative TSSs under the control of the fusion
protein. Indeed, we identified 775 TSS associated with differential
transcription (more than 2-fold change, q < 0.1) in the genome of
Kasumi-1 cells following RUNX1/RUNX1T1 knockdown
(Fig. 7a). Among those, knockdown of the RUNX1/RUNX1T1 led
to differential usage of 112 alternative TSSs (more than 2-fold
change, q < 0.1) (Fig. 7b). Loss of RUNX1/RUNX1T1 increased
chromatin accessibility and RUNX1 occupation at alternative
TSSs to a similar extend as in the total group of TSSs driving
differential transcription (Fig. 7a, Supplementary Fig. 3a). Thus,
perturbation of RUNX1/RUNX1T1 reorganizes the chromatin
structure of alternative TSSs leading to their transcriptional
activation.
The cohort of genes where RUNX1/RUNX1T1 represses
alternative TSSs includes the NAD kinase gene NADK, the
RUNX1T1 paralogue CBFA2T3, the kinase gene RPS6KA1 and
the rhomboid kinase gene PARL (Supplementary Data 6, 7). In
Fig. 7 RUNX1/RUNX1T1 affects differential splicing by controlling alternative transcription start sites (TSSs). a Vulcano plot of the differential
expression from various TSSs in the genome of Kasumi-1 cells following RUNX1/RUNX1T1 knockdown. Differentially expressed TSSs (at least 2-fold change in
expression, p < 0.005, q < 0.1) are shown by vermilion squares. b Differential usage of alternative TSSs in the genome of Kasumi-1 cells after RUNX1/
RUNX1T1 knockdown. Differentially used TSSs (at least 2-fold change in expression, p < 0.0007, q < 0.1) are shown by vermilion squares. c Enrichment of
DNase I hypersensitivity site-Seq reads in the genomic regions surrounding the non-differential TSSs, differentially expressed TSSs or differentially used
TSSs. In this analysis, only TSSs genomic regions that overlap the RUNX1/RUNX1T1 binding peaks were used. In each boxplot, horizontal line represents the
median of expression distribution, box shows the interquartile range, and whiskers are the minimum and maximum. P-values were calculated with two-sided
Mann–Whitney U test. d IGV screen shot showing the RUNX1/RUNX1T1 binding and RNA reads from nascent and total RNA-Seq at the 5’-terminal region of
PARL locus for siMM-treated and siRR-treated Kasumi-1 cells. Exons and exon-exon junctions are designated by the letters E and J, respectively, and
numbered. Differentially used junction J3 is highlighted in purple. Bottom scheme depicting Cufflinks assembled representative full-length transcripts of PARL
gene expressed in Kasumi-1 cells. For each transcript, Cuffdiff based log2 (FC) siRR/siMM and q-values, as well as the size of in silico predicted proteins are
indicated in parentheses. In addition, the positions of the Cuffdiff determined transcription start sites are also shown. At the bottom of panel, the scheme
showing target location of dCas9-KRAB which was targeted to the second RUNX1 consensus site. e Schematic representation of primer binding positions for
qPCR-based validation of the differential splicing in PARL gene. The structure of expected amplicons is shown at the bottom of the figure. f qPCR-based
validation of the differential splicing of PARL transcripts under the two siRNA treatment conditions in the transcriptome of two t(8;21)-positive cell lines. Bars
represent mean ± SD of three independent experiments. g Induction of PARL-03 transcription after RUNX1/RUNX1T1 knockdown with or without induction of
dCas9-KRAB. Bars represent mean ± SD of three independent experiments. P-value was calculated with two-sided Student’s t test.
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each case, loss of RUNX1/RUNX1T1 activated an alternative TSS
that either exclusively affected the 5’-UTR as in the case of
NADK, was predicted to change only the N-terminal amino acids
of the corresponding protein (e.g., CBFA2T3, RPS6KA1) or may
have caused larger N-terminal deletions (e.g., PARL).
For instance, RUNX1/RUNX1T1 occupies the PARL gene that
encodes a kinase controlling mitophagy and apoptosis and that is
associated with clinical outcome of AML (Supplementary
Fig. 3b)44,45. The binding site of RUNX1/RUNX1T1 locates in
the first intron 6.6 kb downstream of the canonical PARL TSS1.
Knockdown of RUNX1/RUNX1T1 eliminated its binding to this
genomic element and activated 3’-proximally located TSS2 and
TSS3 (Fig. 7d, e). In particular transcription of a non-canonical
exon from TSS3 and the corresponding exon-exon junction J3
yielded alternative transcript PARL-03 (Fig. 7d). The observed
increase in total PARL transcript and protein levels in t
(8;21) blasts upon RUNX1/RUNX1T1 knockdown was mainly
due to alternative transcript PARL-03 (Supplementary Fig. 3c, d).
Furthermore, junction J3 was a specific feature of the
transcriptomes of primary AML subtypes with a more mature
immunophenotype than t(8;21) AML, but of neither t(8;21)-
positive AMLs nor normal CD34-positive haematopoietic stem
and progenitor cells (Supplementary Fig. 3e). These data support
the notion that the non-canonical TSS3 is activated in some
AMLs, but is repressed in the t(8;21) AML subtype.
We further examined the functionality of this element by
targeting an endonuclease-deficient dCas9-KRAB repressor to a
site 200 bp upstream of TSS3 (Fig. 7d). Expression of dCas9-
KRAB was induced by addition of doxycycline to the medium.
When compared to mismatch siRNA-treated Kasumi-1 cells,
knockdown of RUNX1/RUNX1T1 caused twentyfold increased
expression of PARL-03 without significantly affecting canonical
PARL-01 levels (Fig. 7g). Induction of dCas9-KRAB did not affect
PARL-01 expression with 0.98 and 1.01fold changes for siMM
and siRR-treated cells, respectively. However, dCas9-KRAB
induction significantly reduced the induction of PARL-03
transcription that was caused by RUNX1/RUNX1T1 loss (Fig. 7g).
These findings confirm that transcription of PARL-03 is regulated
by a promoter located 6.6 kb in canonical intron 1 and further
supports the notion that binding of RUNX1/RUNX1T1 to this
element represses its transcription-activating potential.
Alternatively, loss of RUNX1/RUNX1/T1 binding can also
result in a repression instead of an activation of alternative TSSs
as in the case of LIMS1, where repression of TSS2 led to a
substantially decreased level of LIMS1 protein isoform e
(Supplementary Fig. 4). Thus, similar to canonical regulation of
transcription, RUNX1/RUNX1T1 can both repress and activate
alternative TSSs.
Activation of an alternative TSS in the RPS6KA1 gene com-
pensates for RUNX1/RUNX1T1 loss. Another example for
RUNX1/RUNX1T1-exerted control of an alternative TSS is pro-
vided by the RPS6KA1 locus. RUNX1/RUNX1T1 binds to a site
in intron 1 located 12 kb downstream of TSS1 (Fig. 8a). Loss of
RUNX1/RUNX1T1 binding results in a threefold increase in
transcript and protein levels in t(8;21) AML cells (Fig. 8a, Cuf-
flinks panel; Fig. 8b, c). This increase is mainly due to the
twentyfold activation of TSS2 located in direct proximity down-
stream of the RUNX1/RUNX1T1 binding site.
RPS6KA1 encodes ribosomal kinase 1 (RSK1, pp90RSK1), which
promotes cell proliferation and survival by linking MAPK
signaling to the MTOR pathway and inhibiting pro-apoptotic
and antiproliferative factors including BAD and CDKN1B (also
known as p27)46. Interestingly, RUNX1/RUNX1T-positive AML
expresses significantly lower amounts of RPS6KA1 transcripts
than other AML subtypes (Fig. 8d). Furthermore, high expression
levels of this gene correlate with a worse clinical outcome
(Fig. 8e). We, therefore, wondered if the upregulation of
RPS6KA1 may rescue t(8;21) AML cells from transient
RUNX1/RUNX1T1 loss and the therewith connected to impaired
self-renewal capacity.
To that end we took advantage of the RSK-specific inhibitor
BI-D1870 and examined the impact of RPS6KA1 inhibition on
the clonogenic potential of t(8;21) AML cells as a surrogate read-
out for leukemic self-renewal. In general, RPS6KA1 inhibition
substantially impaired clonogenic growth in a dose-dependent
fashion (Fig. 8f). However, RUNX1/RUNX1T1-knockdown
sensitizes leukemic cells to RPS6KA1 inhibition: BI-D1870 alone
reduced clonogenicity with an apparent IC50 of 600 nM, a
preceding knockdown of RUNX1/RUNX1T1 lowered this value
to 100 nM. In conclusion, alternate TSS usage and therewith
linked increased expression of RPS6KA1 compensated for the loss
of RUNX1/RUNX1T1 strongly suggesting RPS6KA1 as a
pharmacologic target for t(8;21) AML. As target identification
usually focuses on genes and proteins with elevated expression
levels23, these data also prove the value of considering gene
products repressed by an oncogene as candidates for therapeutic
intervention.
RUNX1/RUNX1T1 controls alternative splicing through dif-
ferential expression of splicing factors. Around 60% of the
differential splicing events in Kasumi-1 cells cannot be explained
by proximal RUNX1/RUNX1T1 binding indicating that they are
not under direct control of the fusion protein. However, we and
others have previously shown that t(8;21)-positive leukemia cells
have a specific signature of genes encoding splicing factors and
mRNA surveillance genes expression that may affect splicing
patterns and abundance of RNA isoforms35,47–52. This signature
is so unique that it allows distinguishing leukemic from normal
hematopoietic cells (Supplementary Fig. 5a, b). Moreover, cor-
relation analysis confirmed highly coordinated expression of
genes encoding splicing factors and mRNA surveillance genes
with RUNX1/RUNX1T1 in t(8;21)-harboring AML cells (Sup-
plementary Fig. 5c). Furthermore, RUNX1/RUNX1T1 binding
sites were often present within the genes encoding splicing-
associated factors or in their immediate vicinity (Supplementary
Data 3, 11). Therefore, we speculated that RUNX1/RUNX1T1-
dependent changes in expression of RNA processing genes may
be responsible for differential splicing events in Kasumi-1 cells.
By combining of RNA-Seq (Supplementary Data 1, GSE54478)
and microarray (Supplementary Data 1, GSE29223) data and
three algorithms (Cufflinks/Cuffdiff, DESeq2 and edgeR/limma),
we identified 42 genes encoding splicing factors and 14 mRNA
surveillance genes with statistically significant differential expres-
sion in Kasumi-1 cells following the RUNX1/RUNX1T1 knock-
down (Supplementary Data 11; Fig. 9a, b). Of those, 16 genes
including USB1 are associated with RUNX1/RUNX1T1 binding
sites implying them as direct target genes (Fig. 9c, Supplementary
Data 11).
However, genes encoding splicing factors and mRNA surveil-
lance genes may also indirectly be regulated via fusion protein-
mediated control of transcription factors expression. To test this
hypothesis, we reconstructed gene regulatory network for those
genes encoding splicing factors and mRNA surveillance genes
with significantly changed expression upon RUNX1/RUNX1T1
depletion (Fig. 9d). This network was inferred from microarray,
RNA-Seq and bioinformatics data (see Supplementary Methods
for further details). The reconstructed network suggests a
complex expression interplay between the fusion protein,
transcription factors and the factors involved in splicing and
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mRNA surveillance. Consequently, factors can be classified
according to their response to RUNX1/RUNX1T1 status. One
group comprises RBFOX2 and several hnRNPs (HNRNPDL,
HNRNPLL, and HNRNPR) with changed expression levels upon
RUNX1/RUNX1T1 knockdown, while other hnRNPs such as
HNRNPA3, HNRNPF, and HNRNPH1 were not affected
(Supplementary Data 11).
Based on the above-mentioned predictive model (see section
“Modulation of local epigenetic marks by RUNX1/RUNX1T1
influences alternative splicing”), we developed a short list of
sequence features that represent the most important predictors of
whether an exon-exon junction is differential or not. This short
list included motif frequency and strength for HNRNPA3,
MBNL1, PTBP1, RBFOX2, SRSF7, and YBX1 splicing factors
(Supplementary Data 12). Partial dependence profiling indicated
a strong non-linear relationship between class probability of EEJs
and frequency or strength of splicing regulator motifs. Motifs for
all splicing factors of this list similarly affected the discrimination
between differential versus non-differential splicing events. For
example, there is a positive link between the motif strength of the
YBX1 splicing factor in the 3’-end of the intron and the
probability of diffEEJs, and a mainly negative relationship
between SRSF7 motif score in the downstream exon and
differential splicing (Fig. 9e).
To further validate above mentioned findings, we also
conducted a motif analysis based on several independent splicing
factors binding datasets53–55. This analysis confirmed an
association between motifs for some splicing factors and
differential splicing in the transcriptome of Kasumi-1 cells
following RUNX1/RUNX1T1 knockdown (Supplementary
Data 13). Moreover, our experimental data also indicate the
existence of such a relationship. For instance, the two t(8;21)
Fig. 8 Knockdown of RUNX1/RUNX1T1 leads to differential splicing of RPS6KA1 transcripts in Kasumi-1 cells. a IGV screen shot showing the RUNX1/
RUNX1T1 binding and RNA reads from nascent and total RNA-Seq at the 5’-terminal region of RPS6KA1 locus for siMM-treated and siRR-treated Kasumi-
1 cells. E, exons; J, exon-exon junctions. Bottom scheme depicting RPS6KA1 transcripts. diffEEJs are boxed and highlighted in yellow. b qPCR-based
quantitation of the change in the activity of various transcription start sites of RPS6KA1 gene following RUNX1/RUNX1T1 knockdown. The overall expression
level (“total”) of RPS6KA1 gene is also indicated. *p= 0.029, **p= 0.025, #p= 0.022, and ##p= 0.014 with one-tailed one sample Student’s t-test. Bars
represent mean ± SD of three independent experiments. c Knockdown of RUNX1/RUNX1T1 leads to statistically significant (p= 0.00504 (*)) changes in the
RPS6KA1 protein level in leukemic cells. P-value was calculated using one-tailed one sample Student’s t-test with μ0= 1. Bars represent mean ± SD of three
independent experiments. d Differential expression of RPS6KA1 gene in t(8;21) positive and negative AMLs. Gene expression levels were taken from the
TGCA-LAML (n= 173) and GEO/ENA-AML (n= 80) datasets. For the TGCA-LAML dataset, RSEM values of normalized gene expression were used.
Normalized expression of genes from GEO/ENA-AML dataset was calculated as RPKM. In each violin plot, horizontal yellow line represents the median of
expression distribution, box shows the interquartile range, and whiskers are the minimum and maximum. P-values were calculated with two-sided
Mann–Whitney U test. e Survival of AML patients depending on expression of RPS6KA1 gene. This survival plot is based on TCGA-LAML dataset (n= 173).
The dependence of patient survival on gene expression was calculated according to the Cox proportional hazards regression model. f Impact of RPS6KA1
inhibition on clonogenicity of t(8;21) AML cells. Kasumi-1 cells were electroporated with the indicated siRNAs followed by plating into semisolid medium
containing the indicated concentrations of RPS6KA1 inhibitor. Data was normalized relative to clonogenicity of the siMM electroporated and BI-D1870
untreated leukemia cells. Bars represent mean ± SD of four independent experiments. *p= 0.053, **p= 0.012, #p= 0.008, and ##p= 0.001 with one-
tailed Student’s t-test against respective baseline in untreated cells.
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AML cell lines Kasumi-1 and SKNO-1 express a non-canonically
splice variant of TRAPPC2L lacking exon 4 (Supplementary
Fig. 6)56,57. TRAPPC2L is not a direct target of the fusion
protein, but eCLIP data from K562 cells suggest that SRSF7 binds
to all exons of TRAPPC2L (Supplementary Fig. 6g). Interest-
ingly, while knockdown of RUNX1/RUNX1T1 abolishes skip-
ping of exon 4, depletion of SRSF7 has the opposite effect. In
contrast, RBFOX2 knockdown did not affect exon 4 skipping
(Supplementary Fig. 6h, i). These combined findings suggest that
RUNX1/RUNXT1 corrupts splicing by interfering with SRSF7
function.
Finally, to assess the involvement of RNA surveillance factors
in differential splicing, we compared the distribution of RNA
isoform expression with and without premature translation
Fig. 9 RUNX1/RUNX1T1 indirectly affects differential splicing in Kasumi-1 cells. a Bar graph showing the impact of RUNX1/RUNX1T1 knockdown on the
expression of mRNA surveillance genes (SurG), genes encoding splicing factors (SplG) and transcription factors genes (TFG) associated with splicing. Bars
represent mean ± SD of three independent qPCR experiments. *p < 0.05, **p < 0.01, ***p < 0.001 with one-tailed Student’s t test. b Graph showing
correlation between RNA-seq and q-PCR validation of differential RNA processing gene expression. c IGV screen shot depicting RUNX1/RUNX1T1 binding
and RNA-Seq reads for the USB1 locus. d Cytoscape scheme showing RUNX1/RUNX1T1-centered gene regulatory network of genes encoding splicing
regulators and mRNA surveillance factors. Terms “upregulated genes” and “downregulated genes” refer to a change in the expression of the genes after
RUNX1/RUNX1T1 knockdown. Positively and negatively co-expressed genes linked by green and red edges, respectively. Examples of the genes from each
group are shown in the respective dashed boxes. e Effect of the strength of the motifs to splicing factors on the probability of non-diffEEJs and diffEEJs in
leukemia cells. These partial dependence plots are based on the results from 1,000 independent runs of the random forest meta-classifier and 1000
classification trees per random forest per run.
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termination codons for all the genes with differential splicing.
This analysis did not reveal significant differences between the
two pools of RNA molecules: about 11% of differentially spliced
RNA isoforms contains premature stop codons compared to 14%
of non-differential RNA isoforms (odds ratio 0.81, p-value=
0.470 according to Fisher’s exact test).
Taken together, these findings suggest that besides regulating
differential splicing via direct binding and altering chromatin
structure, RUNX1/RUNX1T1 dysregulates this process by alter-
ing the expression of splicing factors.
RUNX1/RUNX1T1 regulates alternative splicing of PTK2B via
RBFOX2. The PTK2B gene (also known as PYK2) encodes the
focal adhesion kinase 2B, which regulates cell adhesion and
migration, two key processes in leukaemogenesis58. High
Fig. 10 RUNX1/RUNX1T1 controls alternative splicing of PTK2B transcripts in t(8;21)-positive leukemia cells. a Splicing graphs, representative Cufflinks
assembled transcripts and in silico translated proteins of PTK2B gene. This panel is based on Kasumi-1 total RNA-Seq data. Exons and exon-exon junctions
are designated by the letters E and J, respectively, and numbered. Differentially used junction J26 is highlighted in purple. For each transcript, Cuffdiff based
log2 fold changes in expression and respective q-values are indicated in parentheses. a denotes amino acids. b Strip charts demonstrating normalized
expression of exon-exon junctions J24 to J27 in Kasumi-1 cells. Genomic location of junctions is shown in a. Horizontal lines are arithmetic means. P-value
was calculated with two-sided Student’s t test. c and d qPCR-based validation of the differential splicing of PTK2B transcripts under two siRNA treatment
conditions. Binding positions of primers and structure of the expected amplicons are shown in c. Bars in d represent mean of two independent qPCR
experiments. e Pearson correlation heatmap demonstrating relationship between expression of the SRSF7, RBFOX2, or PTK2 genes and splicing events in
the PTK2B gene. This map is based on TCGA-LAML dataset (n= 173). f RBFOX2 and SRSF7 proteins bind PTK2B gene. This genome browser snapshot is
based on ENCODE eCLIP data. g Effect of the siRNA-mediated knockdown of RBFOX2 and SRSF7 expression on splicing of the PTK2B gene in Kasumi-1 cells.
Bars represent mean ± SD of three independent experiments.
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expression levels of this gene are indicative of an inferior clinical
outcome (Supplementary Fig. 7a). The gene is subject to alter-
native splicing: differential splicing of exon 23 results in two
protein isoforms of 1009 and 967 amino acids, with the shorter
one lacking a nuclear/cytoplasmic localization region between the
kinase and the C-terminal focal adhesion targeting domain
(Fig. 10a)59. Analysis of nascent and total RNA-Seq data from
Kasumi-1 cells indicated that RUNX1/RUNX1T1 knockdown led
to increased exon 23 skipping and concomitant joining of exon 22
to exon 24 (Fig. 10b–d). Although RUNX1/RUNX1T1 occupies
the PTK2B locus at several sites, formation of this alternative
junction J26 is unlikely to be directly regulated by the fusion
protein, because its closest binding site locates more than 35 kb
upstream of 5’ splice site of junction J26. Since loss of RUNX1/
RUNX1T1 binding was also associated with a more than twofold
reduced expression of RBFOX2 (Fig. 9a), we examined a potential
of this regulator of alternative splicing in the retention of exon 23.
Analysis of TGCA-LAML and GEO/ENA-AML datasets estab-
lished a negative correlation between RBFOX2 expression and
exon 23 skipping (Fig. 10e; Supplementary Fig. 7b, c). Notably, a
UGCAUG consensus site for RBFOX2 binding is located just 12
nt downstream of this exon and evaluation of ENCODE eCLIP
data for the CML cell line K562 revealed direct association of
RBFOX2 to exon 23 of PTK2B (Fig. 10f).
To examine the impact of RBFOX2 on exon 23 skipping more
directly, we perturbed RBFOX2 expression using two indepen-
dent siRNAs. Either siRNA achieved with 2.5-fold to 4-fold
reduced RBFOX2 levels a similar reduction as RUNX1/RUNX1T1
knockdown (Supplementary Fig. 7d). This loss of RBFOX2 led to
a threefold decreased exon 23 retention again similar to that
achieved by depletion of the fusion protein (Fig. 10g, upper
panel). Notably, knockdown of SRSF7 did not affect exon 23
retention (Fig. 10g, bottom panel). These combined data show
that RUNX1/RUNX1T1 affects alternative splicing of PTK2 by
modulating the expression of RBFOX2.
Discussion
Analyzing modes of malignant dysregulation of the transcriptome
usually separates transcriptional from posttranscriptional control
mechanisms. Consequently, alterations in splicing patterns have
been mainly explored in conjunction with mutations in splicing
factors, while investigations regarding mutated or aberrantly
expressed transcription factors focused on their impact on
transcription6,17. However, most of the latter studies include
genome wide transcriptomic analyses such as total RNA-Seq as
well21, which are affected by post-transcriptional RNA processing
including altered splicing or degradation49. Here, we have
extended such transcription-centered studies by analyzing the
impact of RUNX1/RUNX1T1, a prototype of a leukemic tran-
scriptional regulator, on the generation of alternative transcripts
and found that it controls transcription start site and exon choice.
Such changes can be associated with altered protein sequences
including the generation of isoforms of yet unknown function as
shown here for PARL. We find that RUNX1/RUNX1T1 controls
RNA-isoform expression by preventing alternative initiation of
transcription and, thus, directly link an initiating and driving
oncogenic event with the recently discovered pervasive regulation
of transcription through alternative promoters in cancer cells11.
Our work provides an explanation for potential discordances
between changes in transcript and protein levels following
RUNX1/RUNX1T1 knockdown.
The precise identification of differential splicing events using
RNA-Seq data is not a trivial undertaking; there is no universal
and perfectly reliable bioinformatics tool for this task29,30,60. For
this reason, we employed several algorithms to detect a
comprehensive set of differential splicing events at exon or
exon–exon junction levels with subsequent experimental valida-
tions. Using this approach, we identified 378 genes with sig-
nificantly different RNA splicing maps in Kasumi-1 cells
following the fusion oncogene knockdown. A part of the identi-
fied differential splicing events arises from the differential usage
of alternative transcription starts and is mediated by fusion
protein binding. This result agrees with the observation that
transcription factors regulate alternative splicing by occupying
and modulating alternative promoters61–63.
It was recently suggested that RUNX1/RUNX1T1 may recruit
the splicing of regulatory proteins including proteins with poly(A)
RNA binding activity (i.e., CIRBP, DKC1, GAR1, or RBM3)15.
These data imply a role of the fusion protein in the control of
polyadenylation. Indeed, we found 614 3’-terminal exons that
overlap with RUNX1/RUNX1T1 binding peaks (data not shown).
However, only 4 of these exons were differentially used in the
transcriptome of the siRR-treated versus siMM-treated Kasumi-
1 cells (at least twofold changes, q < 0.0001). Thus, RUNX1/
RUNX1T1 does not substantially affect the selection of mRNA 3’-
termini.
In addition, we found a sub-set of splicing-related genes that
were differentially expressed upon RUNX1/RUNX1T1 knock-
down. This sub-set includes genes encoding classical splicing
regulators (for example, RBM28, RBFOX2, HNRNPLL), as well as
multifunctional genes (for instance, DYRK1A) encoding proteins
with different activities, including components of the nuclear
speckles, which are considered an area of intensive splicing25,26.
According to our data mining and motif analysis results, these
regulatory proteins may additionally contribute to differential
splicing in Kasumi-1 cells following the RUNX1/RUNX1T1
knockdown.
In conclusion, we have shown here that RUNX1/RUNX1T1
regulates alternative RNA splicing for a sub-set of genes in
t(8;21)-positive AML, by controlling the choice of transcriptional
start sites and by modulating expression of splicing components.
These findings add another layer of dysregulation of gene func-
tion by nuclear oncoproteins promoting leukaemogenesis.
Methods
Cell lines. The t(8;21)-positive AML cell lines Kasumi-1 (DSMZ no. ACC 220) and
SKNO-1 (DSMZ no. ACC 690) were obtained from the DSMZ (LGC Standards
GmbH, Wesel, Germany) and cultivated in RPMI1640 containing either 10% fetal
bovine serum (Kasumi-1) or 20% fetal bovine serum and 7 ng/ml GM-CSF
(SKNO-1).
siRNA transfections. Kasumi-1 and SKNO-1 cells (5 × 105 cells/ml) were trans-
fected with 200 nM siRNA in standard culture medium at 330 V (Kasumi-1) or
350 V (SKNO-1) for 10 ms using 4 mm electroporation cuvettes and a Fischer EPI
2500 electroporator (Fischer, Heidelberg, Germany)64. After 15 min at room
temperature, cells were diluted in standard medium to a concentration of 5 × 105
cells/ml. In all the RUNX1/RUNX1T1 knockdown experiments, the previously
established anti-RUNX1/RUNX1T1 active siRR and mismatch control siMM were
used28. All siRNAs used in this study are listed in Supplementary Table 2.
Extraction of total cellular RNA, synthesis of the first strand of cDNA and
qRT-PCR. Total cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN
GmbH, Hilden, Germany) according to the manufacturer’s protocol. Synthesis of
the first strand of cDNA was performed from 1 μg of total cellular RNA in 20 μl
volume using oligo(dT)18 primer and SuperScriptTM III Reverse Transcriptase Kit
(Thermo Fisher Scientific, Carlsbad, USA) according to the manufacturer’s pro-
tocol. Quantitative real-time PCR was carried out in triplicates on StepOnePlus
Real-time PCR System (Thermo Fisher Scientific, Carlsbad, USA) using Quanti-
Tect® SYBR® Green PCR Kit (QIAGEN GmbH, Hilden, Germany) according to the
manufacturer’s protocol. All the primers (Supplementary Data 8 and Supple-
mentary Data 14) for real-time qPCR were designed using Primer-BLAST on-line
tool65.
Extraction of total cellular proteins and Western blotting. Total cellular pro-
teins were extracted simultaneously with the RNeasy Mini Kit-based purification of
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RNA by precipitating the RNeasy flowthrough with 2 volumes of acetone21. Pel-
leted proteins were dissolved in urea buffer (9 M urea, 4% CHAPS (3-((3-chola-
midopropyl) dimethylammonio)-1-propanesulfonate), 1% DTT) and protein
concentrations were measured by Bradford assay.
Western blotting was carried out according to the previously described
protocol29. Rabbit polyclonal anti-RUNX1 (1:1000; cat. #4334S, Cell Signaling
Technology), rabbit monoclonal anti-RPS6KA1 (1:1000; cat. #8408S, Cell Signaling
Technology), mouse monoclonal anti-LIMS1 (1:1000; cat. #11890S, Cell Signaling
Technology), and mouse monoclonal anti-GAPDH (1:10,000; cat. #AM4300,
InvitrogenTM) antibodies were used as primary antibodies. Moreover, two different
rabbit polyclonal antibodies with C-terminal epitopes were used to detect the PARL
proteins: the first one (α-PARL #1; 1:500) was obtained from Thomas Langer’
laboratory44 and the second one (α-PARL #2) was from Abcam (1:1000; cat.
#ab45231). In addition, goat anti-mouse (1:10,000; cat. #P0447, Agilent) or anti-
rabbit (1:10,000; cat. #sc-2004, Santa Cruz Biotechnology) polyclonal
immunoglobulins conjugated with horseradish peroxidase were used as secondary
antibodies.
Nascent RNA-seq. Procedure for nascent RNA isolation, preparation of RNA-Seq
libraries, and massively parallel sequencing was previously described66. Briefly, 108
Kasumi-1 cells were treated with 500 μM 4-thiouridine for 1 h. Cells were lysed
using TRI Reagent® (Sigma-Aldrich, St Louis, USA) and RNA was purified
according to the manufacturer’s instruction. Next, 4-thiouridine-incorporated
RNA was biotinylated by labeling with 1 mg/ml Biotin-HPDP (Abcam, Cambridge,
UK) for 90 min at room temperature. Following chloroform extraction, labeled
RNA was separated using magnetic streptavidin beads, beads were washed, and
RNA was eluted in two rounds of elution with 100 μl 100 mM DTT. Finally, RNA
was purified using RNeasy MinElute Cleanup Kit (QIAGEN GmbH, Hilden,
Germany) and samples were sequenced using Illumina HiSeqTM 2000 paired-end
sequencing.
Publicly available high-throughput datasets used in the study. Our public
microarray dataset included data on 106 primary samples of bone marrow or
peripheral blood from patients with t(8;21)-positive AML, and 85 samples of bone
marrow-derived CD34-positive cells (BM), 32 samples of bone marrow mono-
nuclear cells (BM-MNC) and 100 samples of peripheral blood mononuclear cells
(PB-MNC) from healthy donors (Supplementary Data 1). CEL files of the selected
microarrays were downloaded from the NCBI GEO repository67, converted into
CHP files, and primary data matrix was corrected against the background, log2-
transformed and quantile normalized by the robust multi-array averaging algo-
rithm using Affymetrix Expression ConsoleTM (Thermo Fisher Scientific,
Carlsbad, USA).
The subsequent datasets were downloaded from European Nucleotide Archive
as FASTQ files generated on the Illumina HiSeqTM 2000/2500 platform. Datasets
comprised RNA-Seq data on primary samples from 20 patients each with either
t(8;21)-positive AML, karyotypically normal AML (KN), inv(16)-positive AML and
different rearrangements of the MLL gene (MLLr). Furthermore, they comprised
20 samples each of normal bone marrow-derived CD34-positive cells (BM),
umbilical cord blood-derived CD34-positive cells (CB) and mobilized normal
peripheral blood-derived CD34-positive cells (PB) (Supplementary Data 1).
Annotated public datasets. All annotations of human genome were downloaded
from Ensembl database in GTF/GFF format32. We used Ensembl release 85 based
on GRCh38.p7 reference assembly of human genome. Genomic coordinates of the
CpGs islands in the human genome were downloaded via FTP server of UCSC
Genome Browser68. The whole set of GenBank human mRNA and ESTs sequences
was downloaded via FTP server of UCSC Genome Browser in GTF format. We
used sequences that were pre-aligned against the GRCh38/hg38 reference assembly
of the human genome with BLAT69. Any sequences with mismatches and less than
four aligned blocks were removed. In addition, sequences with the exon length <25
bp and intron length <50 bp were filtered out.
Statistical analysis. Statistical analyses for each experiment were performed as
described in the text body or in the corresponding figure legends. Data between
groups were compared, unless otherwise specified, using a two-sided Student’s t-
test, Mann–Whitney U test, χ2-test or Fisher’ exact test. All data are presented as
mean ± SD. Differences between groups were considered statistically significant at
p < 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Nascent RNA next-generation sequencing has been submitted to the Gene Expression
Omnibus (accession number GSE160792). Total RNA-Seq, ChIP-Seq, and DNase-Seq
samples were previously deposited in the Gene Expression Omnibus (accession numbers
GSE54478 and GSE29222). Publicly available high-throughput datasets used in the study
are described in Supplementary Data 1. All other relevant data supporting the key
findings of this study are available within the article, supplementary information or from
the corresponding authors upon request. Source data are provided with this paper.
Code availability
All R codes of this study were deposited at GitHub software project
TranscriptomicFeatures (https://github.com/VGrinev/TranscriptomicFeatures)70. These
codes are freely available under GNU General Public License v3.0.
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